MONTREAL, QUEBEC--(MARKET WIRE)--Sep 12, 2007 -- ProMetic Life Sciences Inc. (Toronto:PLI.TO - News) ("ProMetic") announces the expansion of its clinical program for its orally active drug PBI-1402 for the treatment of anemia in patients with myelodysplastic syndrome ("MDS"), a condition often referred to as "pre-leukemia" and diagnosed in 25,000 individuals in North America annually.
